Clinical Study of the Use of Amino Acid Peritoneal Dialysate in Diabetic Patients

Inclusion criteria

• Type I or II diabetes patients aged 18 to 75 years (including 18 and 75 years), regardless of gender;
• Stable peritoneal dialysis patients who have undergone peritoneal dialysis treatment for ≥ 3 months;
• Use 3-5 bags of peritoneal dialysis solution daily;
• 6.0%<glycated hemoglobin (HbA1c) level ≤ 8.5%;
• 90g/L ≤ Hemoglobin concentration ≤ 130g/L
• Stable use of erythropoietin and rosuvastatin;
• The fluctuation of carbohydrate energy supply ratio in the first 3 months before enrollment is less than 15%;
• Not using amino acid (15) peritoneal dialysis solution for the first 3 months before enrollment;
• Within the past month, the patient's prescription for hypoglycemic drugs has not been adjusted;
• Within the past month, the patient's dietary structure and food intake have remained stable.

Exclusion criteria

• Peritonitis has occurred within the past 3 months;
• Use Acodextrin peritoneal dialysis solution;
• Contraindications for the presence of amino acids (15) in peritoneal dialysis fluid:

• Individuals allergic to any component of amino acid (15) peritoneal dialysis fluid;
• Serum urea level>38 mmol/l;
• Metabolic acidosis (CO2 binding capacity<22mmol/L);
• Severe hypokalemia (blood potassium<2.5mmol/L);
• Various congenital amino acid metabolism abnormalities;
• Liver dysfunction (alanine aminotransferase levels exceeding 2.5 times the upper limit of normal);
• Combined hemoglobinopathies: such as thalassemia, sickle cell disease, etc;
• It is expected that kidney transplantation may be accepted during the trial period;
• Participated in other clinical studies.